Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Infectious Diseases|August 15, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b studyRobert McMahon, Sebastian Toepfer, Natascha Sattler, et al.
The Lancet. Infectious Diseases|June 5, 2020
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trialNina Wressnigg, Romana Hochreiter, Oliver Zoihsl, et al.
Lancet (London, England)|June 15, 2023
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialMartina Schneider, Marivic Narciso-Abraham, Sandra Hadl, et al.
Nature Medicine|February 6, 2026
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trialPetronela Weisová, Susanne Scheiblauer, Jacqueline Ecker, et al.
Clinical and Vaccine Immunology : CVI|September 5, 2014
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu latoNina Wressnigg, P Noel Barrett, Eva-Maria Pöllabauer, et al.
Plos One|April 15, 2011
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1Brigitte M Krenn, Andrej Egorov, Ekaterina Romanovskaya-Romanko, et al.
Critical Care (London, England)|March 6, 2020
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trialChristopher Adlbrecht, Raphael Wurm, Pieter Depuydt, et al.
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
The Lancet. Infectious Diseases|September 7, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescentsVera Buerger, Sandra Hadl, Martina Schneider, et al.
Pageof 2